PL2786754T3 - Leczenie skojarzone inhibitorem mitozy - Google Patents

Leczenie skojarzone inhibitorem mitozy

Info

Publication number
PL2786754T3
PL2786754T3 PL14175268T PL14175268T PL2786754T3 PL 2786754 T3 PL2786754 T3 PL 2786754T3 PL 14175268 T PL14175268 T PL 14175268T PL 14175268 T PL14175268 T PL 14175268T PL 2786754 T3 PL2786754 T3 PL 2786754T3
Authority
PL
Poland
Prior art keywords
combination therapy
mitotic inhibitor
mitotic
inhibitor
therapy
Prior art date
Application number
PL14175268T
Other languages
English (en)
Inventor
Victoria MONEO OCAÑA
Luis Francisco GARCÍA FERNÁNDEZ
Carlos María GALMARINI
María José GUILLÉN NAVARRO
Pablo Manuel AVILÉS MARÍN
Gema Santamaría Núñez
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of PL2786754T3 publication Critical patent/PL2786754T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14175268T 2010-11-12 2011-11-11 Leczenie skojarzone inhibitorem mitozy PL2786754T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10382300 2010-11-12
PCT/EP2011/069976 WO2012062920A1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid
EP11781807.0A EP2637663B1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid
EP14175268.3A EP2786754B1 (en) 2010-11-12 2011-11-11 Combination therapy with a mitotic inhibitor

Publications (1)

Publication Number Publication Date
PL2786754T3 true PL2786754T3 (pl) 2019-07-31

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
PL11781807T PL2637663T3 (pl) 2010-11-12 2011-11-11 Terapia skojarzona z alkaloidem przeciwrakowym
PL14175268T PL2786754T3 (pl) 2010-11-12 2011-11-11 Leczenie skojarzone inhibitorem mitozy
PL14175282T PL2786756T3 (pl) 2010-11-12 2011-11-11 Terapia skojarzona z inhibitorem topoizomerazy
PL14175259T PL2786753T3 (pl) 2010-11-12 2011-11-11 Leczenie skojarzone inhibitorem mitozy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11781807T PL2637663T3 (pl) 2010-11-12 2011-11-11 Terapia skojarzona z alkaloidem przeciwrakowym

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL14175282T PL2786756T3 (pl) 2010-11-12 2011-11-11 Terapia skojarzona z inhibitorem topoizomerazy
PL14175259T PL2786753T3 (pl) 2010-11-12 2011-11-11 Leczenie skojarzone inhibitorem mitozy

Country Status (24)

Country Link
US (5) US20130266666A1 (pl)
EP (6) EP2786754B1 (pl)
JP (4) JP6382516B2 (pl)
KR (9) KR20170096065A (pl)
CN (3) CN103282037B (pl)
AU (4) AU2011328004C1 (pl)
BR (4) BR122017028566B1 (pl)
CA (4) CA2995033C (pl)
CY (4) CY1117466T1 (pl)
DK (4) DK2786756T3 (pl)
ES (4) ES2569180T3 (pl)
HK (1) HK1202422A1 (pl)
HR (4) HRP20160361T1 (pl)
HU (4) HUE042801T2 (pl)
LT (3) LT2786753T (pl)
ME (3) ME02395B (pl)
PL (4) PL2637663T3 (pl)
PT (3) PT2786756T (pl)
RS (4) RS60236B1 (pl)
RU (4) RU2605335C2 (pl)
SI (4) SI2786754T1 (pl)
SM (4) SMT201900190T1 (pl)
TR (2) TR201903859T4 (pl)
WO (1) WO2012062920A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
HUE042801T2 (hu) * 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
CA2975223C (en) * 2015-01-30 2021-08-24 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
CA3008960C (en) * 2016-01-11 2024-07-02 Syndevrx, Inc. TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020087077A1 (en) 2018-10-26 2020-04-30 Syndevrx,Inc. Biomarkers of metap2 inhibitors and applications thereof
EP4025217A1 (en) * 2019-09-03 2022-07-13 Pharma Mar, S.A. Lurbinectedin in the treatment of malignant mesothelioma
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
PH12022551216A1 (en) * 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
EP4176880A4 (en) * 2020-07-01 2024-07-03 New Cancer Cure - Bio Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A 3-KETOACYL-COA THIOLASE INHIBITOR AND AN INHIBITOR OF CARNITINE ACYLCARNITINE TRANSPORTERS
CN118576601A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗结肠癌的药物中的用途
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN115957188A (zh) * 2021-06-17 2023-04-14 中国医学科学院医药生物技术研究所 米铂脂质体在抗耐药性肿瘤的应用
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof
WO2024188978A1 (en) * 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025228597A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE69936845T2 (de) 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
ATE299146T1 (de) 2000-04-12 2005-07-15 Pharma Mar Sa Ecteinaschidin derivate mit antikrebs wirkung
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
KR100718946B1 (ko) * 2000-11-06 2007-05-16 파르마 마르, 에스.에이. 효과적인 항종양 치료
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
PL375713A1 (pl) 2002-08-19 2005-12-12 Pfizer Products Inc. Terapia skojarzona do leczenia chorób hiperproliferacyjnych
MXPA05004133A (es) 2002-10-18 2005-10-05 Pharma Mar Sau Nuevos compuestos antitumorales.
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
MXPA06013902A (es) * 2004-05-28 2007-01-26 Pfizer Prod Inc Procedimiento para tratar el crecimiento de celulas anormal.
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
JP5345323B2 (ja) * 2004-12-15 2013-11-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 癌を処置するための治療剤の組合せ
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
WO2009140675A2 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
HUE042801T2 (hu) * 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval

Also Published As

Publication number Publication date
HK1202419A1 (en) 2015-10-02
HK1202422A1 (en) 2015-10-02
US20180078550A1 (en) 2018-03-22
HUE049389T2 (hu) 2020-09-28
RU2767664C2 (ru) 2022-03-18
CA2995018C (en) 2021-04-20
ME03408B (me) 2020-01-20
EP2786754A2 (en) 2014-10-08
CA2995025A1 (en) 2012-05-18
CY1121504T1 (el) 2020-05-29
EP3666275A2 (en) 2020-06-17
BR122017028570B1 (pt) 2022-03-03
CN105664165A (zh) 2016-06-15
EP2786755A2 (en) 2014-10-08
CA2995025C (en) 2020-04-28
RS58608B1 (sr) 2019-05-31
EP2786756B1 (en) 2020-03-11
KR102247982B1 (ko) 2021-05-04
RU2605335C2 (ru) 2016-12-20
PL2637663T3 (pl) 2016-08-31
ME03501B (me) 2020-04-20
KR20190130078A (ko) 2019-11-20
HUE042801T2 (hu) 2019-07-29
KR20170124641A (ko) 2017-11-10
AU2011328004A1 (en) 2013-05-30
CA2995033A1 (en) 2012-05-18
CY1121501T1 (el) 2020-05-29
EP2786754B1 (en) 2019-01-09
LT2786753T (lt) 2019-04-10
AU2016200191A1 (en) 2016-02-04
RS60236B1 (sr) 2020-06-30
WO2012062920A1 (en) 2012-05-18
RU2743643C2 (ru) 2021-02-20
ES2790414T3 (es) 2020-10-27
SI2786756T1 (sl) 2020-07-31
HK1202421A1 (en) 2015-10-02
CN103282037A (zh) 2013-09-04
EP2786756A2 (en) 2014-10-08
CN106860870B (zh) 2020-03-31
PT2786754T (pt) 2019-04-24
BR112013011480B1 (pt) 2022-03-22
CN103282037B (zh) 2017-04-05
CA2995018A1 (en) 2012-05-18
SMT202000211T1 (it) 2020-05-08
PT2786753T (pt) 2019-04-24
JP2016138133A (ja) 2016-08-04
CY1122904T1 (el) 2021-10-29
SI2637663T1 (sl) 2016-05-31
RU2018102080A (ru) 2019-07-19
KR20170096065A (ko) 2017-08-23
BR122017028566B1 (pt) 2022-03-03
DK2786753T3 (en) 2019-04-15
KR101716804B1 (ko) 2017-03-15
KR20170057472A (ko) 2017-05-24
SMT201900190T1 (it) 2019-05-10
EP2637663B1 (en) 2016-02-24
RU2013126630A (ru) 2014-12-20
SI2786754T1 (sl) 2019-05-31
SMT201600112B (it) 2016-07-01
KR20170058454A (ko) 2017-05-26
KR20130140071A (ko) 2013-12-23
SMT201900186T1 (it) 2019-05-10
EP2786756A3 (en) 2014-10-29
KR20170096224A (ko) 2017-08-23
SI2786753T1 (sl) 2019-05-31
CA2817420C (en) 2019-09-24
EP2786755A3 (en) 2014-10-29
HRP20200696T1 (hr) 2020-07-24
EP2637663A1 (en) 2013-09-18
JP2013542241A (ja) 2013-11-21
US20230404999A1 (en) 2023-12-21
DK2637663T3 (en) 2016-04-18
LT2786754T (lt) 2019-04-10
RU2018102078A (ru) 2019-07-19
HK1202423A1 (en) 2015-10-02
LT2786756T (lt) 2020-05-11
HK1188572A1 (zh) 2014-05-09
AU2017276155A1 (en) 2018-01-04
RU2018102078A3 (pl) 2021-04-20
JP2018100303A (ja) 2018-06-28
JP6724056B2 (ja) 2020-07-15
HRP20190565T1 (hr) 2019-05-17
US11590129B2 (en) 2023-02-28
BR122017028568B1 (pt) 2022-03-03
ME02395B (me) 2016-09-20
CY1117466T1 (el) 2017-04-26
RU2757373C2 (ru) 2021-10-14
AU2016200191B2 (en) 2018-01-18
CA2995033C (en) 2020-04-28
AU2011328004B2 (en) 2016-07-14
ES2569180T3 (es) 2016-05-09
US20180008602A1 (en) 2018-01-11
RS58609B1 (sr) 2019-05-31
US20130266666A1 (en) 2013-10-10
CA2817420A1 (en) 2012-05-18
BR112013011480A8 (pt) 2018-01-02
RS54648B1 (sr) 2016-08-31
ES2719052T3 (es) 2019-07-08
PL2786756T3 (pl) 2020-07-13
KR20160088956A (ko) 2016-07-26
PT2786756T (pt) 2020-05-07
KR102301175B1 (ko) 2021-09-10
HUE027516T2 (en) 2016-10-28
JP6723815B2 (ja) 2020-07-15
JP6382516B2 (ja) 2018-08-29
ES2719091T3 (es) 2019-07-08
RU2016144668A3 (pl) 2020-03-25
EP2786753B1 (en) 2019-01-09
PL2786753T3 (pl) 2019-09-30
TR201904459T4 (tr) 2019-05-21
KR102452022B1 (ko) 2022-10-06
BR112013011480A2 (pt) 2016-08-09
JP6724055B2 (ja) 2020-07-15
HRP20190554T1 (hr) 2019-05-03
DK2786756T3 (en) 2020-04-27
KR20210046853A (ko) 2021-04-28
DK2786754T3 (en) 2019-04-15
AU2017276155B2 (en) 2019-03-07
TR201903859T4 (tr) 2019-04-22
US20180078551A1 (en) 2018-03-22
AU2017276157A1 (en) 2018-01-04
AU2011328004C1 (en) 2017-01-19
RU2016144668A (ru) 2018-12-18
JP2018100302A (ja) 2018-06-28
RU2018102080A3 (pl) 2021-04-12
EP2786753A2 (en) 2014-10-08
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
EP3666275A3 (en) 2020-09-09
HUE042802T2 (hu) 2019-07-29
AU2017276157B2 (en) 2019-03-07
EP2786754A3 (en) 2014-10-29
CN106860870A (zh) 2017-06-20

Similar Documents

Publication Publication Date Title
HRP20190565T1 (hr) Kombinacijska terapija s inhibitorom mitoze
HUS1800042I1 (hu) Antivirális terápia
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
SG10201406545TA (en) A well
GB2486690B (en) Autoinjectors
GB201015799D0 (en) Autoinjectors
GB201021717D0 (en) Autoinjectors
EP2611352A4 (en) DISHWASHER
GB201007327D0 (en) A fireseal
GB2486681B (en) Autoinjectors
GB201021716D0 (en) Autoinjectors
GB201005394D0 (en) Therapy
GB201002966D0 (en) A bedchair
SG10201508839RA (en) Repositioning A Value Axis
EP2629766A4 (en) COMBINATION THERAPY
GB201012981D0 (en) Pineapple pups
PH32010000289S1 (en) A ballpen
PH32010000777S1 (en) A can
GB201001497D0 (en) A metronome
ZA201107348B (en) A carry arrangement
GB201002874D0 (en) A grip
PH32010000526S1 (en) A luminaire
GB201021722D0 (en) Autoinjectors